What is Complix?
Complix is a specialized biopharmaceutical enterprise focused on the development of transformative Cell Penetrating Alphabody (CPAB) therapeutics. By targeting intracellular disease pathways associated with cancer and autoimmune disorders, the company is redefining the boundaries of traditional drug discovery. Their proprietary Alphabody platform enables the creation of novel therapeutic interventions, including potential non-injectable delivery methods, which significantly expands the reach of modern biopharmaceuticals. As a key player in the life sciences ecosystem, Complix bridges the gap between complex molecular biology and scalable clinical applications, aiming to provide solutions for patients with limited treatment options.
How much funding has Complix raised?
Complix has raised a total of $22.3M across 3 funding rounds:
Series A
$6.2M
Series B
$15.5M
Grant
$600K
Series A (2010): $6.2M with participation from Vesalius Biocapital Partners, Lrm, and CRP Sante
Series B (2013): $15.5M led by Edmond de Rothschild Investment Partners, Gimv, TrustCapital, OMNES Capital, CRP-Sante, Baekeland Fund, and Vesalius Biocapital Partners
Grant (2017): $600K, investors not publicly disclosed
Key Investors in Complix
Vesalius Biocapital Partners
A venture capital firm specializing in innovative life science companies in Europe, with a focus on therapeutics, medical devices, and diagnostics.
Edmond de Rothschild Investment Partners
An established investment banking firm founded in 1923, providing comprehensive financial services and strategic capital solutions.
Lrm
A venture capital provider focused on economic development and innovation, supporting sustainable growth through smart capital and business incubation.
What's next for Complix?
Looking ahead, Complix is poised to leverage its recent capital infusion to accelerate its product pipeline and solidify its market position. The strategic focus remains on expanding the utility of the Alphabody platform through targeted partnerships and rigorous clinical validation. By prioritizing the development of candidates that address high-unmet-need disease states, the company is well-positioned to transition from a research-intensive entity to a clinical-stage powerhouse. Future growth will likely be driven by the successful execution of its R&D roadmap and the potential for licensing its proprietary technology to larger pharmaceutical entities, thereby maximizing the commercial impact of its innovative therapeutic portfolio.
See full Complix company page
